Results
Two Phase 1 studies concluded in June 2022 by the University of Glasgow in conjunction with SQ Innovation.
Goals of Studies
- Compare the effectiveness of the novel subcutaneous furosemide (Lasix® SQF) versus the traditional intravenous (IV) furosemide formula – through the following measures:
- Bioavailability (amount of drug that enters the body)
- Pharmacodynamic parameters (action of the drug on the body)
- Diuresis (amount of urine output)
- Natriuresis (amount of sodium in urine)
- Pharmacokinetics (movement of drug in the body over time)
- Identify any adverse events, infusion site pain, skin irritation, or device failure associated with the Lasix SQF Infusor device
- Understand patient acceptability of the Lasix SQF treatment
Summary of Results
- The novel subcutaneous furosemide (Lasix SQF) infused over 5 hours resulted in complete bioavailability (amount of drug that enters the body) to intravenous (IV) furosemide administered as a single dose.
. - Lasix SQF resulted in similar results in terms of diuresis (amount of urine output) and natriuresis (amount of sodium excreted) when compared to IV furosemide
. - Using the Lasix SQF Infusor was feasible and well-tolerated by patients
Details of Results
BIOAVAILABILITY
Bioavailability (amount of drug that enters the body) of Lasix® SQF versus IV furosemide was 112%.
Furosemide given by single IV bolus dose is rapidly excreted with the first voids and hence the slightly lower number for IV.
PHARMACODYNAMIC PARAMETERS
Pharmacodynamic parameters describe the action of the drug on the body. The study looked at two result outcomes related to pharmacodynamic parameters.
Lasix SQF resulted in similar results in terms of diuresis (amount of urine output) and natriuresis (amount of sodium in urine) when compared to IV furosemide. On average Lasix SQF resulted in 3.5L diuresis over 24hrs when compared to 3.0L with IV.
Diuresis is more spread-out with the slow infusion when compared to IV bolus. It starts slightly later but lasts considerably longer. This tempered diuretic was selected to give a patient a more comfortable experience while preserving the full diuretic response.
Diuresis (amount of urine output)
Natriuresis (amount of sodium excreted)
PHARMACOKINETICS
Pharmacokinetics is the activity of drugs in the body over time, including the processes by which drugs are absorbed, distributed in the body, localized in the tissues, and excreted.
The plasma furosemide time curves show the expected differences:
-
- IV bolus results in a very high peak value that is about 7 times higher than the average maximum level with the 5hr infusion
- Plasma levels with the Infusor reach levels sufficient for diuresis in less than 1hr
- Effective plasma levels are maintained for more than 6 hours
The second study conducted at the University of Glasgow showed that the Lasix SQF Infusor in hospitalized heart failure patients performed well. Plasma levels at 1 and 4 hours after start resulted in similar plasma levels as the first study.
This study showed that more than enough Lasix® SQF stayed in the body long enough to provide appropriate and effective therapeutic treatment.
ADVERSE EFECTS
- Events: No treatment related adverse events were identified.
- Infusion Site Pain: 95% of the participants reported no or minimal pain.
- Skin irritation: 4 out of 20 participants had minor, transient skin reaction.
- Adhesion: The device adhered well in 19 of the 20 participants. One Infusor came loose after approximately 1 hour and 25 mins. This was attributed to profuse sweating which prevents the adhesive from bonding to the skin.
PATIENT ACCEPTABILITY
The Lasix SQF Infusor was determined to have excellent usability.
The median System Usability Scale score was 99 (where 100 was a maximal score); 14 (70%) participants scored above 85.
Up Next
A large randomised controlled trial, co-sponsored by NHS (National Health Service) began in June 2022 in the UK and the University of Glasgow. This trial investigates the effectiveness and safety of Lasix® SQF delivered in a home environment (compared to usual care strategy with IV furosemide delivered in hospital) in patients hospitalised with heart failure.
Sign up for our mailing list to stay informed on the results of this trial.